Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by TILT Biotherapeutics

TILT Biotherapeutics Announces Final Close of €22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials
From TILT Biotherapeutics
Via Business Wire
TILT Biotherapeutics Announces Boston Office Opening as it Expands its Clinical Trials in the US
From TILT Biotherapeutics
Via Business Wire
TILT Biotherapeutics Announces First US Patient Dosed in Immunotherapy Clinical Trial in Ovarian Cancer
From TILT Biotherapeutics
Via Business Wire
TILT Biotherapeutics Collaborates with MSD on Immunotherapy Clinical Trial in Checkpoint Inhibitor Refractory Non-Small Cell Lung Cancer
From TILT Biotherapeutics
Via Business Wire
TILT Biotherapeutics Announces over $10 Million Financing to Advance Oncology Immunotherapy Assets
From TILT Biotherapeutics
Via Business Wire
TILT Biotherapeutics Announces Positive Update on its Phase 1 Immunotherapy Clinical Trials in Cancer
From TILT Biotherapeutics
Via Business Wire
TILT Biotherapeutics Announces Data at ESMO on Its Oncolytic Immunotherapy Platform
From TILT Biotherapeutics
Via Business Wire
TILT Biotherapeutics Reports Publication on its Oncolytic Immunotherapy Platform in Pancreatic Cancer
From TILT Biotherapeutics
Via Business Wire
TILT Biotherapeutics Submits IND for Phase I Trial of Immunotherapeutic TILT-123 in Ovarian Cancer
From TILT Biotherapeutics
Via Business Wire
TILT Biotherapeutics, Docrates Cancer Center and Helsinki University Hospital Open Cancer Immunotherapy Clinical Trial
From TILT Biotherapeutics
Via Business Wire
TILT Biotherapeutics and MSD to Collaborate on Clinical Trial of Adenoviral Cancer Immunotherapeutic TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer
From TILT Biotherapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.